Camizestrant
Brand names: Etcamah · Active ingredient: Camizestrant
In short: ETCAMAH in combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer upon detection of ESR1
What is Camizestrant used for?
ETCAMAH in combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer upon detection of ESR1 mutation during aromatase inhibitor and CDK4/6 inhibitor therapy, based on an FDA-authorized test .
This indication is approved under accelerated approval based on progression-free survival as measured from detection of ESR1 mutation . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
âš Boxed warning (FDA's strongest warning)
ETCAMAH in combination with ribociclib, a QTc interval prolonging drug and a strong CYP3A inhibitor, or in combination with other QTc interval prolonging drugs, can increase the risk of Torsades de Pointes, other ventricular arrhythmias, and sudden death (5.1, 5.2, 7.1).
Avoid concomitant use of ETCAMAH with products (other than ribociclib) known to prolong the QTc interval and/or have a known risk of Torsades de Pointes. If concomitant use with other products cannot be avoided, monitor the QTc interval more frequently (5.1, 7.3).
Obtain ECG prior to initiation and monitor heart rate and QTc interval during treatment. Assess and correct electrolyte abnormalities prior to initiation and during treatment. Withhold ETCAMAH until resolution of QTc interval prolongation and resume or permanently discontinue ETCAMAH based on severity. (2.2, 2.4)
Camizestrant dosage
Select patients with HR-positive, HER2-negative locally advanced or metastatic breast cancer who have received at least 6 months of an aromatase inhibitor and CDK4/6 inhibitor therapy for treatment with ETCAMAH in combination with a CDK4/6 inhibitor based on the presence of an ESR1 mutation in plasma specimens, using an FDA-authorized test performed every 3 months until an ESR1 mutation has been detected .
Information on FDA-authorized tests for the detection of an ESR1 mutation in breast cancer is available at: http://www.fda.gov/CompanionDiagnostics.
Perform an electrocardiogram (ECG) prior to initiating ETCAMAH, then every week for the first 2 weeks of treatment, and periodically during treatment as clinically indicated .
Monitor heart rate more frequently during the first 30 days of treatment with ETCAMAH in patients with bradycardia (resting heart rate less than 60 bpm) at baseline and those on concomitant medications known to lower heart rate (e.g., beta-blockers) .
The recommended dosage of ETCAMAH is 75 mg orally once daily, with or without food, until disease progression or unacceptable toxicity .
Administer ETCAMAH in combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib). Continue the CDK4/6 inhibitor at the same dosage as when the ESR1 mutation was detected. Refer to the Prescribing Information of the CDK4/6 inhibitor for additional dosing information .
Take ETCAMAH at approximately the same time each day.
Swallow tablets whole. Do not cut, crush, or chew tablets prior to swallowing. Do not take broken, cracked, or otherwise not intact tablets.
If a dose is missed within 6 hours, take the missed dose. If a dose of ETCAMAH is missed for more than 6 hours, skip the dose for the day and take the next dose at the usual time.
If a dose is vomited, do not take an additional dose and take the next dose at the usual time.
The recommended dosage modifications for ETCAMAH for adverse reactions are provided in Table 1. No dose reductions of ETCAMAH are recommended.
Adverse Reaction | Severity
Severity as defined by NCI CTCAE version 5.0. | ETCAMAH Dosage Modifications
QTc Interval Prolongation
| QTc > 500 msec or QTc > 480 msec and prolongation from baseline > 60 msec | Withhold ETCAMAH.
If other contributing causes are identified, then treat or correct the contributing causes.
Resume ETCAMAH when QTc returns to < 480 msec.
Re-assess ECGs weekly for the first 2 weeks of treatment, and periodically during treatment as clinically indicated.
Permanently discontinue ETCAMAH if QTc interval prolongation is either > 500 msec or > 60 msec change from baseline AND associated with any of the following: Torsades de Pointes, polymorphic ventricular tachycardia, syncope, or signs/symptoms of serious arrhythmia. …
How to take Camizestrant — instructions & advice from the label
Advise the patient to read the FDA approved patient labeling (Patient Information).
QTc Interval Prolongation
Inform patients ETCAMAH is indicated to be used in combination with a CDK4/6 inhibitor and there is potential risk of additional QTc interval prolongation when combined with ribociclib and/or products that can cause QTc interval prolongation, which may increase the risk of Torsades de Pointes, other ventricular arrhythmias, and sudden death. Advise patients that ECG will be monitored before treatment and thereafter. Advise patients or caregivers to seek immediate medical attention if they suspect or develop signs or symptoms associated with clinical consequences of QTc interval prolongation. Instruct patients to consult with their healthcare provider prior to taking other drugs that cause QTc interval prolongation with ETCAMAH .
Bradycardia
Inform patients ETCAMAH causes decrease in heart rate. Advise patients that heart rate will be monitored more frequently during the first 30 days of treatment with ETCAMAH in patients with bradycardia (heart rate less than 60 bpm) at baseline and those on concomitant medications known to lower heart rate. …
Warnings & precautions
Do not take this medicine if: None.
ETCAMAH in combination with a CDK4/6 inhibitor is associated with QTc interval prolongation .
When ETCAMAH is used in combination with ribociclib, a CDK4/6 inhibitor that causes QTc interval prolongation and is a strong CYP3A inhibitor, there is potential for an increased risk of Torsades de Pointes, other ventricular arrhythmias, and sudden death. One case of Torsades de Pointes was observed in a dose-finding trial when ETCAMAH was used with ribociclib .
In SERENA 6, QTc interval prolongation occurred in 2.6% of patients treated with ETCAMAH in combination with a CDK4/6 inhibitor. QTc interval prolongation led to dose interruption of ETCAMAH in 0.6% of patients. ETCAMAH also causes bradycardia, which increases the risk of QTc interval prolongation. .
Perform an ECG prior to initiating ETCAMAH, then every week for the first 2 weeks of treatment, and periodically during treatment as clinically indicated .
Obtain serum electrolytes at baseline and during treatment as clinically indicated, and correct electrolyte abnormalities.
Avoid concomitant use of ETCAMAH in combination with a CDK4/6 inhibitor with products that can cause QTc interval prolongation, are strong CYP3A inhibitors, and/or drugs known to lower heart rate .
Withhold or permanently discontinue ETCAMAH based on severity .
ETCAMAH causes a decrease in heart rate. Bradycardia increases the risk for life-threatening arrhythmias and sudden death when concomitant QTc interval prolongation is present, such as when ETCAMAH is used in combination with ribociclib, both a QTc interval prolonging product and a strong CYP3A inhibitor .
In SERENA-6, bradycardia adverse events occurred in 8% of patients treated with ETCAMAH. The mean heart rate decrease from baseline was approximately 13 beats per minute (bpm) with ETCAMAH with the maximum decrease observed on Day 15. …
Camizestrant side effects
The following clinically significant adverse reactions are described elsewhere in the labeling:
•QTc interval prolongation
•Bradycardia
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer
The safety of ETCAMAH was evaluated in 155 patients with HR-positive, HER2-negative locally advanced or metastatic breast cancer with detectable ESR1 mutation without disease progression during first line treatment with an aromatase inhibitor (AI) in combination with a CDK4/6 inhibitor in SERENA-6 . Patients received ETCAMAH 75 mg orally once daily in combination with a CDK4/6 inhibitor (N = 157) or AI in combination with a CDK4/6 inhibitor (N = 158).
The median duration of exposure to ETCAMAH in combination with a CDK4/6 inhibitor was 10.1 months.
Serious adverse reactions occurred in 10% of patients who received ETCAMAH in combination with a CDK4/6 inhibitor. Serious adverse reactions in > 1% of patients included urinary tract infection, pneumonia, and osteonecrosis of jaw (1.3% each). Fatal adverse reactions occurred in 1.3% of patients who received ETCAMAH in combination with a CDK4/6 inhibitor, including acute respiratory distress syndrome and sudden death (0.6% each). …
Drug interactions
Table 5 describes drug interactions where concomitant use of another drug affects ETCAMAH.
Strong CYP3A Inhibitors
Prevention or Management | •Monitor for increased adverse reactions to ETCAMAH and modify the dosage as recommended .
Mechanism and Clinical Effect | •Camizestrant is a CYP3A substrate. Concomitant use with strong CYP3A inhibitors increases camizestrant plasma concentrations , which may increase the risk of adverse reactions related to ETCAMAH.
•ETCAMAH is indicated to be used in combination with CDK4/6 inhibitors, including ribociclib, which is a strong CYP3A inhibitor and can prolong the QT interval .
Strong and Moderate CYP3A Inducers
Prevention or Management | •Avoid concomitant use of strong CYP3A inducers.
•The co-administration of ETCAMAH and a moderate CYP3A inducer is allowed with caution.
•The dosage recommendations for concomitant use of moderate CYP3A inducers differ depending on the CDK4/6 inhibitor used in combination with ETCAMAH.
oAvoid concomitant use of moderate CYP3A inducers for patients who are receiving ETCAMAH in combination with abemaciclib or palbociclib. …
About this medicine
ETCAMAH tablets contain camizestrant, an estrogen receptor antagonist for oral use. The chemical name is N-[1-(3-fluoropropyl)-3-azetidinyl]-6-[(6S,8R)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3H-pyrazolo[4,3-f]isoquinolin-6-yl]-3-pyridinamine. Camizestrant is white to brown powder. The molecular formula for camizestrant is C24H28F4N6 and the molecular weight is 476.51 g/mol. The chemical structure for camizestrant is shown below:
Each ETCAMAH tablet contains 75 mg camizestrant and the following inactive ingredients: anhydrous dibasic calcium phosphate, magnesium stearate, microcrystalline cellulose, and sodium starch glycolate. The tablet film-coating consists of ferric oxide red, ferric oxide yellow, ferrosoferric oxide, polyethylene glycol 3350, polyvinyl alcohol, talc and titanium dioxide.
How it works: Camizestrant is an estrogen receptor (ER) antagonist. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID c54223d3-f3c7-4186-afa0-429d84805826. Read the full official label on DailyMed.
Related medicines
Levothyroxine Allopurinol Ondansetron Finasteride Clonidine Testosterone Thyroid Methotrexate